

12th November 2025
IOLCP/CGC/2025

National Stock Exchange of India Ltd

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

Security Symbol: IOLCP

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai – 400 001

Security Code: 524164

Subject: Investor Presentation-Q2 & H1 FY26.

Dear Sir,

Please find enclosed herewith the Investor Presentation on the Financial Results of the Company for the quarter and half year ended 30th September 2025. This presentation is being submitted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This presentation is also made available on the Company's website www.iolcp.com

Hope you will find the same in order.

Thanking You,


Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh
Sr. Vice President & Company Secretary



IOL Chemicals and Pharmaceuticals Limited

Investor Presentation Q2 & H1 FY26



Q2 & H1 FY26 Performance



CEP Certification for Pantoprazole Sodium Sesquihydrate Process-III

- EDQM issued a Certificate of Suitability (CEP) for Pantoprazole Sodium Sesquihydrate Process-III on 14th October 2025, enabling exports to Europe and other CEP-compliant markets
- Pantoprazole sodium is a proton pump inhibitor (PPI) that reduces stomach acid and is used to treat conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome.

Incorporation of IOL Pharmaxis UK Limited

- Incorporated IOL Pharmaxis UK Limited (wholly owned subsidiary) in October 2025 in UK
- The subsidiary will strengthen IOL's international operations in its core Pharmaceuticals and Chemicals business, expanding its global reach.

Q2 & H1 FY26 Standalone Performance Highlights



Q2 FY26



₹ 567.5 Cr

Revenue from Operations

▲ **7.9% YoY**



₹ 64.0 Cr

EBITDA

▲ **33.3% YoY**
EBITDA Margin **11.1%**



₹ 30.0 Cr

Profit After Tax

▲ **56.7% YoY**
PAT Margin **5.2%**

H1 FY26



₹ 1,119.2 Cr

Revenue from Operations

▲ **8.9% YoY**



₹ 133.5 Cr

EBITDA

▲ **25.7% YoY**
EBITDA Margin **11.8%**



₹ 64.0 Cr

Profit After Tax


▲ **31.0% YoY**
PAT Margin **5.6%**

Q2 & H1 FY26 Standalone Performance Highlights




Pharmaceuticals

(In ₹ Cr)




Chemicals

(In ₹ Cr)



Geographical Break-up



Standalone Profit & Loss Statement – Q2 & H1 FY26



Particulars (in INR Cr.)	Q2 FY26	Q2 FY25	Y-o-Y	Q1 FY26	Q-o-Q	H1 FY26	H1 FY5	Y-o-Y
Revenue from Operations	567.5	525.8	7.9%	551.7	2.9%	1,119.2	1,028.1	8.9%
Other Income	6.9	6.4		7.4		14.3	13.8	
Total Revenue	574.4	532.2	7.9%	559.1	2.7%	1,133.5	1,041.9	8.8%
Cost of Materials Consumed	366.7	351.8		376.6		743.3	674.8	
Purchase of Traded Goods	0.0	0.0		0.0		0.0	0.0	
Changes in Inventories of Finished Goods and Work in Progress	1.5	3.9		-12.3		-10.9	17.2	
Employee Benefits Expense	63.4	58.7		57.7		121.0	111.8	
Other Expenses	78.9	69.9		67.7		146.6	132.0	
EBITDA	64.0	48.0	33.3%	69.5	-8.0%	133.5	106.2	25.7%
EBITDA %	11.1%	9.0%		12.4%		11.8%	10.2%	
Depreciation and Amortisation Expense	20.0	17.9		19.8		39.7	34.7	
EBIT	44.0	30.1	46.4%	49.8	-11.6%	93.8	71.4	31.3%
Finance Costs	3.5	4.1		4.2		7.7	6.3	
PBT	40.5	25.9	56.2%	45.5	-11.0%	86.1	65.2	32.1%
Total Tax Expense*	10.5	6.8		11.6		22.1	16.3	
Profit for the year	30.0	19.2	56.7%	34.0	-11.7%	64.0	48.8	31.0%
PAT %	5.2%	3.6%		6.1%		5.6%	4.7%	
EPS	1.02	0.65		1.16		2.18	1.66	

Profitability was marginally impacted on a sequential basis due to higher fuel costs, following the Punjab floods, which temporarily disrupted supply chains and elevated energy inputs.

Standalone Balance Sheet



Particulars (in INR Cr.)	Sep 25	Mar 25
ASSETS		
Non-current assets		
(i) Property, plant and equipment	1,127.9	1158.0
(ii) Right to Use Asset		
(iii) Capital Work in progress	64.5	20.8
(iv) Other Intangible Assets	11.6	12.3
(v) Intangible Assets under development	2.4	1.1
(vi) Financial Assets		
- Investments	17.7	17.7
- Other Financial Assets	34.2	7.9
(vii) Other Non- Current Assets	14.2	12.8
Total Non-current assets	1,272.4	1230.7
Current assets		
(i) Inventories	384.3	360.6
(ii) Financial Assets		
- Investments	3.5	3.3
- Trade receivables	523.1	513.7
- Cash and cash equivalents	27.2	78.0
- Bank balances other than above	141.0	129.9
- Other financial Assets	7.6	5.6
(iii) Current Assets (net)	0.0	0.3
(iv) Other Current Assets	53.9	59.6
Total Current Assets	1,140.4	1151.1
TOTAL ASSETS	2,412.9	2381.8

Particulars (in INR Cr.)	Sep 25	Mar 25
EQUITY AND LIABILITIES		
EQUITY		
(i) Equity share capital	58.7	58.7
(ii) Other equity	1,692.4	1628.7
Total Equity	1,751.1	1687.4
LIABILITIES		
Non-current liabilities		
(i) Financial Liabilities		
-Borrowings		
-Lease Liabilities		
(ii) Provisions	7.5	6.7
(iii) Deferred tax Liabilities (net)	80.4	77.8
(iv) Other Non-Current Liabilities	0.0	0.0
Total Non-Current Liabilities	87.8	84.5
Current liabilities		
(i) Financial liabilities		
-Borrowings	159.0	117.0
-Lease Liabilities		
-Trade payables	355.8	427.6
-Other financial liabilities	42.0	46.2
(ii) Other Current Liabilities	11.7	17.1
(iii) Provisions	2.2	2.0
(iv) Current Tax Liabilities	3.2	0.0
Total Current Liabilities	573.9	609.9
TOTAL EQUITY AND LIABILITIES	2,412.9	2381.8

Standalone Cash Flow Statement




Particulars (in INR Cr.)	Sep 25	Sep 24
Cash Flow from Operating Activities		
Profit before Tax	86.1	65.2
Adjustment for Non-Operating Items	41.1	37.5
Operating Profit before Working Capital Changes	127.1	102.6
Changes in Working Capital	-100.1	-89.6
Cash Generated from Operations	27.0	13.1
Less: Direct Taxes paid	-15.9	-16.2
Net Cash from Operating Activities	11.1	-3.1
Cash Flow from Investing Activities	-96.2	-75.6
Cash Flow from Financing Activities	34.2	89.4
Net increase/ (decrease) in Cash & Cash equivalent	-50.9	10.7
Cash and cash equivalents at the beginning of the year	78.0	7.5
Cash and cash equivalents at the end of the year	27.2	18.2



At a Glance

Journey So Far



Business Overview






Team size of **3000+** employees

Among the top global producers of **Iso Butyl Benzene (IBB)**

Existing Facility: Spanning **180+ acres**
Expansion: Acquired **101 acres** on Chandigarh-Bathinda Highway for new site development

Zero Discharge Effluent Treatment Plant

Largest producer of **Ibuprofen** and the only company worldwide being fully backward integrated



Customer base across **80 countries**

DSIR-approved R&D facility with **50+ scientists** driving innovation across APIs and specialty chemicals

Over **20** products are commercialized with **9** products in pipeline

Major producer of Ethyl Acetate in India with a capacity of **1,00,000 MTPA**, and Acetic Anhydride with a capacity of **25,000 MTPA**

Debt to Equity Ratio **0.07**

Segment Overview- Pharmaceuticals



Largest global producer of Ibuprofen, with an annual capacity of 12,000 MT

World's only company with complete backward integration

Commenced a fully backward-integrated Unit-11 for Paracetamol manufacturing at Barnala, with an installed capacity of 10,800 MTPA

15 DMFs with USFDA

CEP certification received for 18 APIs; 2 additional CEP applications currently under review with EDQM

The state-of-the-art facility comprises 11 dedicated units focused on efficient, high-quality production across a diversified product range

Existing Product Portfolio

Ibuprofen

Ibuprofen Lysinate

Ibuprofen Sodium

Dex-Ibuprofen

Metformin HCL

Paracetamol

Clopidogrel

Pantoprazole Sodium

Fenofibrate

Levetiracetam

Lamotrigine

Losartan Potassium

Application across therapeutic areas



Anti – Inflammatory



Analgesic & Antipyretic



Anti - Diabetic



Anti - Convulsant



Anti - Platelet



Anti – Epileptic



Anti- Cholesterol




Proton Pump Inhibitor



Anti- Hypertension

Strategic Shift Towards High-Value APIs



Segment Overview- Specialty Chemicals



Among the largest global manufacturers of Iso Butyl Benzene (IBB) worldwide


Ethyl Acetate manufacturing capacity of over 1,00,000 MTPA

Producing Acetic Anhydride with capacity of 25,000 MTPA - for captive and merchant sale


Asia's first continuous dual technology plant for MCA and Acetyl Chloride using green chemistry

REACH-certified for Ethyl Acetate & Acetic Anhydride, enabling exports to EU Market


Product Portfolio




Ethyl Acetate
1,00,000 MTPA




Acetic Anhydride
25,000 MTPA
(Major Input for Paracetamol)



Iso Butyl Benzene
12,000 MTPA
(KSM for Ibuprofen)



Mono Chloro Acetic Acid
7,200 MTPA
(Input for Ibuprofen)



Acetyl Chloride
5,200 MTPA
(Input for Ibuprofen)

Addressing Diverse Segments



Pharmaceuticals



Flexible Packaging



Food Processing



Paints



Ink



Textiles



Pesticides




Chemical Intermediates

Pharmaceuticals- A Key Focus



Significant Increase in Pharma's Share of Segmental Revenue



Expanding the non-Ibuprofen Business			
	Installed Capacity	Regulatory Filings*	Therapeutic Area
Metformin Hydrochloride	7200 MTPA	USDMF, CEP & ANVISA GMP Approved, China DMF Active	Anti-Diabetic
Fenofibrate	Multiproduct Plant	USDMF, CEP & ANVISA GMP Approved, China DMF Active	Anti-Cholesterol
Paracetamol (Acetaminophen)	10,800 MTPA	USDMF Under Review, CEP & ANVISA GMP Approved	Analgesic & Anti-pyretic
Levetiracetam	Multiproduct Plant	USDMF Under Review, CEP & ANVISA GMP Approved	Anti-Epileptic
Clopidogrel Bisulphate	240 MTPA	USDMF Filed, CEP & ANVISA GMP Approved, China DMF Under Review	Anti-Platelet
Pantoprazole Sodium	240 MTPA	USDMF Filed, CEP & ANVISA GMP Approved	Proton Pump Inhibitor
Lamotrigine	Multiproduct Plant	USDMF Filed, CEP & ANVISA GMP Approved	Anti-Convulsant
Losartan Potassium	Multiproduct Plant	USDMF Filed, CEP & ANVISA GMP Approved	Anti-Hypertensive

* Some of the listed products are also registered with other major regulatory authorities such as Korea, Taiwan and Russia

Manufacturing Facilities



API manufactured in batch manner and intermediates & Specialty chemicals in continuous product delivery manner based on DCS technology

Dedicated and multiproduct blocks involved in manufacturing of APIs

Facility is coupled with ISO class-8 HVAC system, PSA Nitrogen & Purified water along with 185 MTPH steam generation capacity with multiple boilers

Manufacturing facilities involves – Reactions, Filtration, Centrifugation, Drying, Blending & Sieving, Micronization operation

Four stage treatment zero discharge ETP, solvent recovery plants & EHS cell as a part of the facility

Dedicated decentralized utilities from -20 to 275 deg.C temp and dedicated co-generation plant of 17MW



From Lab to Launch: 20 Products Commercialized, 9 More in Pipeline — R&D at the Heart of Our Growth Story

3

Patents

15

DMFs with USFDA

20

CEPs with EDQM

(18 Approved, 2 Under Review)



A 120-member highly skilled team, including 50+ scientists, driving innovation across key focus areas



Working on generic molecules with latest equipment & techniques for process development



DSIR approved facility for research & development



In-house development of multi step products

Certifications & Accreditations



Approved USFDA facility since 2015, recertified in 2019	EUGMP Certification in 2013, 2017 & Recertification in 2020	Certificate of Suitability from EDQM	Certified Halal in accordance with Shariah Board Guidelines	Certificate of DMF Registration From MFDS Korea	ISO 9001:2015, 14001:2015 & 45001:2018
Certified Kosher	Certified WHO GMP (COPP)	Written confirmation from CDSCO	ISO 27001 & ISO 37001	REACH Certificate for ethyl acetate, enabling exports to 40+ countries worldwide.	GMP Certificate by Ministry of Industry and Trade of the Russian Federation
Ecovadis Silver Medal for FY 2025-26	State Food and Drug Administration Manufacturing License, GMP	Social Accountability Standard	CDE of NMPA approval to export Metformin Hydrochloride to China Market in 2024	Approved ANVISA, Brazil GMP for 10 API Facilities	

Core Management Team



Varinder Gupta | (Managing Director)

Wide and rich experience of more than 38 years in the chemical & fertilizer industry and along with a comprehensive approach and strong Pharma API industry oversight has paved a way for innovation and excellence.



Vikas Gupta | (Joint Managing Director)

Academically equipped with knowledge and possesses organizational capacity. He has worked in strategic department of the Company and played a main role in guiding Chemical and Pharmaceutical business of the company. He has been vital to the functioning of the company over the last 12 years.



Abhiraj Gupta | (Executive Director)

Possesses requisite qualification and experience in the Company's business. He oversees the non-ibuprofen API and chemical business, R&D, regulatory, digital marketing, and strategic decisions. The non-ibuprofen API business is doing good and meeting its targets under his leadership.



Kushal Kumar Rana | (Director – Works)

Master's degree in Chemistry. Over 33 years in the pharmaceutical industry in companies like Morepen Laboratories, Chemiplast Industries. His expertise lies in looking after quality assurance, quality control & corporate regulatory affairs.

Board of Directors



Rajender Mohan Malla
(Chairman and Independent Director)

- With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs
- In his most recent executive roles, he was MD & CEO of PTC India Financial Services Limited (PFS), and prior to that CMD of IDBI.



Sharad Tyagi
(Independent Director)

- Over 38 years of intrapreneurship in India and international markets in diverse industries including pharmaceuticals, OTC, automotive catalysts and specialty chemicals
- Most recently until December 2020, he was the Managing Director for Boehringer Ingelheim (BI) (2009-2020), India.



Harpal Singh
(Independent Director)

- Over 37 year's experience of banking and financial services
- Most recently he was General Manager of Punjab National Bank and headed entire operations of bank in State of Punjab from 2010 to 2015.



Ms Rajni Jha
(Independent Director)

- Ms. Rajni Jha is a accomplished Senior Pharmaceutical Regulatory, Quality, and Compliance professional with over 32 years of experience.
- An esteemed IIT Kanpur scholar with an M.Sc. in Synthetic Organic Chemistry from Kanpur University,
- Held leadership roles at top Indian pharmaceutical giants, including Ranbaxy, Torrent, and Glenmark Pharma.

Ensuring a Sustainable Tomorrow Through ESG Initiatives



Awarded EcoVadis Silver Medal recognizing strong ESG Performance & Global Sustainability Leadership; Ranks Among the Top 15% companies globally



- Committed towards making a difference in the lives of communities surrounding our operations through our CSR efforts and Supporting 17 UNSDGs by being member of UNGC (United Nations Global Compact)
- We strive to create sustainable and meaningful change through our philanthropic efforts, reflecting our core values and commitment to social responsibility.
- SA 8000 : 2014 Social Accountability Standard Certified Organization
- Organization has successfully completed SEDEX (SMETA) Audit on 4 Pillar approach.

- Committed to becoming carbon neutral by 2050
- 100 % State of the art Zero liquid Discharge (ZLD) Facility
- Our continuous efforts have resulted in 6.75% reduction in Combined Scope-01 + Scope 2 and 14 % in Scope 3 greenhouse gas (GHG) emissions during FY 2024-25
- Product Carbon Footprint Study for all Key Products and reduction plan in place
- 572.1 KW solar panels installed in FY 2024-25 to achieve a reduction 500MTCO2e/annum and 667 KW solar panel is planned for FY 2025-26
- Approx. 60,000 trees are maintained within company premises. Carbon Sink verification completed for one plantation area which contributes 79.21 MT CO2e/year in carbon sequestration
- Our targets include a reduction in Combined Scope-01 + Scope 2 emissions by 58.8 %
- 100% reduction in Scope-02 emissions and 35% Reduction in Scope 3 by 2033 ,based on the baseline emissions of FY 2022-23.

- Defined responsibilities for Environment, Health, Safety, and Sustainability (EHS&S) have been clearly established across our sustainability leaders within the organization
- We prioritize strong and effective corporate governance to ensure the best interests of all our stakeholders
- Organization is awarded with Responsible care logo for three years by Indian Chemical Council (ICC)
- Organization is ISO 27001 Information security management system certified and ISO 37001 Anti bribery management system certified.



100%

Water neutral



100%

Zero Liquid Discharge (ZLD)



0

Frequency and severity rate



80%

Power requirement met via renewable energy



6.75%

Reduction in Combined Scope-01 + Scope 02 GHG Emission



71 Score/ 89th %ile

Ecovadis Silver Medal CDP Water Security Score " B" and Supplier Engagement Score " A-"

The background of the slide features a complex, three-dimensional molecular structure. It consists of numerous spherical atoms, some of which are transparent and contain smaller internal structures, connected by thin, light-colored rods representing chemical bonds. The overall color palette is a gradient of teal and green, with the molecular model appearing as a semi-transparent overlay.


Industry Overview

API Industry- Overview




Global API Market Size (In USD Bn)

North America holds over 38% of the API market in 2024. Asia-Pacific—led by India and China posts the fastest growth at 8.7% CAGR.



Indian API Market Size (In USD Bn)

India is the 3rd largest API producer globally, contributing 8% to the market, with over 500 distinct APIs and 57% of WHO's prequalified APIs.



Growth Drivers for Indian API Market

Government Incentives

The Indian government launched a ₹6,940 crore PLI scheme in 2020, offering 6-year incentives for 41 critical APIs and KSMs.

Robust Regulatory Compliance

India leads globally with 752 USFDA-approved pharmaceutical manufacturing facilities as of 2024, the highest number outside the U.S.

Diversification of Global Supply Chains

COVID-19 exposed API supply risks. As a result, global pharma companies are diversifying their supply chains. With a strong manufacturing base and policy support, India is emerging as a key alternative to China for API sourcing.

Increased R&D Investments

One of the key trends in India's pharmaceutical industry is the sharp rise in R&D investment. Companies are focusing on biosimilars, complex generics, and new chemical entities (NCEs) to drive innovation and strengthen global competitiveness.

Quality Manufacturing

India's lower labor and production costs make it a competitive global manufacturing hub, enabling the production of high-quality drugs and vaccines at economical rates compared to developed countries.


Rising Exports

Pharmaceutical exports from India were valued at USD 27.9 billion in FY 2023-24, showcasing a growth of 18.7% compared to the previous year. Indian pharma companies are expanding their footprint into emerging markets like Africa, Latin America, and Southeast Asia.


Specialty Chemicals Industry- Overview




Global Spec. Chem Market Size



Indian Spec. Chem Market Size



Region wise Spec. Chem Market Size Growth (FY25-30)



Key Highlights

- Asia Pacific led the specialty chemicals market in 2024 with a 41.05% share, fueled by growing demand from rapidly industrializing economies like China and India
- India is the second-largest market for specialty chemicals in the Asia-Pacific region, supported by strong demand from pharmaceuticals, agrochemicals, and personal care sectors
- India enjoys a strong cost advantage in specialty chemicals, with labor and power costs significantly lower than global averages. This has positioned the country as a key growth hub in the global specialty chemicals landscape.

India's Rising Role



China + 1 Strategy



Lower Manufacturing Cost



Favourable Government Policies



Export Growth Momentum
(15-20% Growth)



Skilled Manpower Availability



Proximity to Feedstock & Raw Material Availability




Historical Performance


Historical Standalone Performance




Revenues




EBITDA & EBITDA %



Cash Profit After Tax




Segmental Revenue




■ Pharmaceuticals ■ Chemicals (net of intersegment)

Cash Flow from Operations



Capex Spent



Summary Statement of Standalone Profit and Loss



Particulars (in INR Cr.)	FY25	FY24	FY23	FY22
Revenue from Operations	2079.2	2,132.8	2,217.1	2,184.0
Other Income	22.4	30.1	25.6	32.0
Total Revenue	2101.6	2,162.9	2,242.7	2,216.1
Cost of Materials Consumed	1358.3	1,435.1	1,536.1	1,578.9
Purchase of Traded Goods	0.0	0.2	29.2	43.9
Changes in Inventories of Finished Goods and Work in Progress	33.5	-38.3	-18.2	-52.3
Employee Benefits Expense	216.6	201.0	168.2	141.3
Other Expenses	268.6	303.3	275.3	215.9
EBITDA	224.6	261.6	252.1	288.3
EBITDA %	10.7%	12.1%	11.2%	13.0%
Depreciation and Amortisation Expense	71.9	62.9	46.1	43.3
EBIT	152.7	198.7	206.0	245.1
Finance Costs	14.8	16.1	16.5	8.3
Exceptional Items	0.0	0.0	0.0	13.9
PBT	137.9	182.6	189.5	222.8
Total Tax Expense	36.9	47.2	49.5	57.2
Profit for the year	101.0	135.4	140.0	165.7
PAT %	4.8%	6.3%	6.2%	7.5%
EPS	3.44	4.61	4.77	5.64

Summary Statement of Standalone Balance Sheet



Particulars (in INR Cr.)	Mar 25	Mar 24	Mar 23	Mar 22
ASSETS				
Non-current assets				
(i) Property, plant and equipment	1,158.0	921.1	750.5	559.5
(ii) Right to Use Asset	0.0	0.0	0.1	1.0
(iii) Capital Work in progress	20.8	99.8	81.4	102.0
(iv) Other Intangible Assets	12.3	11.6	0.7	0.2
(v) Intangible Assets under development	1.1	1.0	8.2	3.2
(v) Financial Assets				
- Investments	17.7	17.7	17.7	0.1
- Other Financial Assets	7.9	48.9	233.9	205.3
(vi) Other Non- Current Assets	12.8	24.4	9.0	10.3
Total Non-current assets	1,230.7	1124.5	1101.5	881.6
Current assets				
(i) Inventories	360.6	424.8	325.5	409.9
(ii) Financial Assets				
- Investments	3.3	2.9	2.6	2.4
- Trade receivables	513.7	471.2	505.3	469.8
- Cash and cash equivalents	78.0	7.5	1.0	1.1
- Bank balances other than above	129.9	135.1	19.9	136.8
- Other financial Assets	5.6	7.1	3.8	23.0
(iii) Current Tax Assets (net)	0.3	6.8	1.8	0.9
(iv) Other current assets	59.6	64.0	59.3	34.9
Total Current Assets	1,151.1	1119.5	919.1	1,078.7
TOTAL ASSETS	2,381.8	2244.0	2020.6	1,960.3

Particulars (in INR Cr.)	Mar 25	Mar 24	Mar 23	Mar 22
EQUITY AND LIABILITIES				
EQUITY				
(i) Equity share capital	58.7	58.7	58.7	58.7
(ii) Other equity	1,628.7	1552.6	1447.8	1331.6
Total Equity	1,687.4	1611.3	1506.6	1390.3
LIABILITIES				
Non-current liabilities				
(i) Financial Liabilities				
-Borrowings	0.0	0.0	0.0	0.0
-Lease Liabilities	0.0	0.0	0.0	0.2
(ii) Provisions	6.7	6.7	1.7	3.0
(iii) Deferred tax Liabilities (net)	77.8	66.1	56.4	53.2
(iv) Other non-current liabilities	0.0	0.0	0.1	0.3
Total Non-Current Liabilities	84.5	72.9	58.2	56.6
Current liabilities				
(i) Financial liabilities				
-Borrowings	117.0	32.8	79.6	42.8
-Lease Liabilities	0.0	0.0	0.2	1.0
-Trade payables	427.6	469.2	314.2	409.3
-Other financial liabilities	46.2	37.6	36.0	30.0
(ii) Other Current Liabilities	17.1	16.9	17.8	23.0
(iii) Provisions	2.0	3.4	8.1	7.3
Total Current Liabilities	609.9	559.8	455.9	513.4
TOTAL EQUITY AND LIABILITIES	2,381.8	2244.0	2020.6	1,960.3

Summary Statement of Standalone Cashflow




Particulars (in INR Cr.)	Mar 25	Mar 24	Mar 23	Mar 22
Cash Flow from Operating Activities				
Profit before Tax	137.9	182.6	189.5	222.8
Adjustment for Non-Operating Items	79.8	59.8	44.4	33.1
Operating Profit before Working Capital Changes	217.7	242.4	233.9	256.0
Changes in Working Capital	-20.7	90.1	-63.7	-102.3
Cash Generated from Operations	197.0	332.5	170.2	153.6
Less: Direct Taxes paid	-18.3	-42.0	-47.1	-62.6
Net Cash from Operating Activities	178.7	290.5	123.1	91.0
Cash Flow from Investing Activities	-154.2	-191.4	-119.2	-120.6
Cash Flow from Financing Activities	46.0	-92.5	-4.1	-1.6
Net increase/ (decrease) in Cash & Cash equivalent	70.5	6.6	-0.2	-31.2
Cash and cash equivalents at the beginning of the year	7.5	1.0	1.1	32.3
Cash and cash equivalents at the end of the year	78.0	7.5	1.0	1.1




Backward Integration for Margin and Supply Chain Resilience

The company adopts a strategic approach of **backward integration** for key raw materials and intermediates once products achieve significant economies of scale, ensuring enhanced control over supply, cost efficiencies, and quality



Product Diversification Beyond Ibuprofen

The **non-Ibuprofen share** in the pharmaceuticals segment has increased from **18% to 34%** over the past five years, with a strong trajectory to further drive revenue and margin expansion over the next 2–3 years. Key products include Paracetamol, Metformin, Clopidogrel, Fenofibrate, and Pantoprazole



Export Contribution to Rise

With **15 DMFs** and **20 CEPs** filed (**18 approved, 2 under review**), the company is well-placed for regulated market expansion. Aiming to grow **export revenue share** to **~40%**



Scaling Through Land Acquisition

The company has **acquired 101 acres of land** alongside the **Chandigarh-Bathinda Highway**, near its existing facility, to support future expansion. It is in the process of securing clearances for industrial use, environmental compliance, and NHAI approvals

Thank You

COMPANY :



IOL Chemicals And Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Ltd.

CIN : L24116PB1986PLC007030

Mr. Abhay Raj Singh - Sr. VP & Company Secretary

E-mail: investor@iolcp.com

www.iolcp.com

INVESTOR RELATIONS ADVISORS :



MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of
MUFG Pension & Market Services

Ms. Prachi Ambre

prachi.ambre@in.mpms.mufg.com

Mr. Irfan Raeen

irfan.raeen@in.mpms.mufg.com

Meeting Request

Link



Website: <https://in.mpms.mufg.com/>